OmniAb, Inc. OABI

Company Overview

OmniAb, Inc. is a biotechnology platform company focused on antibody discovery technologies for pharmaceutical and biotechnology partners. The company licenses proprietary transgenic animal platforms and related discovery tools that enable partners to identify and develop therapeutic antibodies for a wide range of disease areas, including oncology, immunology, infectious diseases, neuroscience, and metabolic disorders. OmniAb operates within the broader biotechnology and life sciences tools industries, with revenue primarily derived from technology access agreements, research funding, milestone payments, and royalties tied to successful therapeutic commercialization.

The company originated from the antibody discovery business historically developed within Ligand Pharmaceuticals and became an independent publicly traded company in 2022 through a spin-off transaction. OmniAb’s strategic positioning is centered on offering a diversified suite of antibody discovery platforms designed to generate fully human or engineered antibodies with high specificity and therapeutic potential. Its technology portfolio includes transgenic rodents, chickens, and other discovery systems intended to broaden epitope coverage and improve antibody diversity relative to traditional approaches.